Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, a ...